» Articles » PMID: 33329860

Validity and Reliability of the Patient Activation Measure® (PAM®)-13 Malay Version Among Patients with Metabolic Syndrome in Primary Care

Overview
Specialty Public Health
Date 2020 Dec 17
PMID 33329860
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: The Patient Activation Measure (PAM) is one of the most extensively used, widely translated, and tested instruments worldwide in measuring patient activation levels in self-management. This study aimed to determine the validity and reliability of the PAM-13 Malay version among patients with Metabolic Syndrome (MetS) attending a primary care clinic.

Methods: This work is a cross-sectional validation study among patients with MetS attending a university primary care clinic in Selangor. The PAM-13 Malay version underwent a validation process and field testing. Psychometric properties were examined using principal component analysis (PCA) with varimax rotation, scree plot, Monte Carlo simulation, internal consistency, and test-retest reliability analyses.

Results: The content of the PAM-13 Malay version and the original version were conceptually equivalent. The questionnaire was refined after face validation by 10 patients with MetS. The refined version was then field-tested among 130 participants (response rate 89.7%). The Kaiser-Meyer-Olkin test was 0.767, and Bartlett's test of sphericity was ≤0.001, indicating sampling adequacy. Two factors were identified and labeled as (1) Passive and Building Knowledge, and (2) Taking Action and Maintaining Behavior. These labels were chosen as they were conceptually consistent with the items representing the levels of activation in PAM-13. The validated PAM-13 Malay version consisted of 13 items, framed into two domains. The overall Cronbach's α was 0.79, and the intraclass correlation coefficient was 0.45.

Conclusions: The PAM-13 Malay version is valid, reliable, and fairly stable over time. This questionnaire can be used to evaluate the levels of activation among patients with MetS in primary care in Malaysia.

Citing Articles

Digital Solution to Support Medication Adherence and Self-Management in Patients with Cancer (SAMSON): Pilot Randomized Controlled Trial.

Dang T, Wickramasinghe N, Jayaraman P, Burbury K, Alexander M, Whitechurch A JMIR Form Res. 2025; 9:e65302.

PMID: 39969972 PMC: 11888109. DOI: 10.2196/65302.


Patient autonomy in self-managing their bronchial asthma exacerbation and its associated factors, 2024.

Abdulwehab S, Kedir F Front Allergy. 2024; 5:1483897.

PMID: 39525398 PMC: 11543570. DOI: 10.3389/falgy.2024.1483897.


A Systematic Review of the Reliability and Validity of the Patient Activation Measure Tool.

Ng Q, Liau M, Tan Y, Tang A, Ong C, Thumboo J Healthcare (Basel). 2024; 12(11).

PMID: 38891154 PMC: 11171848. DOI: 10.3390/healthcare12111079.


The Patient Activation Measure-13 (PAM-13) in an oncology patient population: psychometric properties and dimensionality evaluation.

Roesel I, Froehlich D, Joos S, Valentini J, Mauch H, Martus P Health Qual Life Outcomes. 2024; 22(1):39.

PMID: 38764032 PMC: 11103863. DOI: 10.1186/s12955-024-02255-w.


Validation of the Arabic Version of the Patient Activation Measure (PAM-13) for Application within the Primary Healthcare Context in Saudi Arabia.

Kerari A, Almalki M, Bahari G, Alharbi M Healthcare (Basel). 2023; 11(23).

PMID: 38063658 PMC: 10706281. DOI: 10.3390/healthcare11233090.


References
1.
Cunha C, Nepomuceno E, Manzato R, Cunha D, da Silva D, Aparecida Spadoti Dantas R . Cultural adaptation and validation of the Brazilian Version of the Patient Activation Measure-22 items. Rev Bras Enferm. 2018; 71(4):1891-1898. DOI: 10.1590/0034-7167-2016-0470. View

2.
Packer T, Kephart G, Ghahari S, Audulv A, Versnel J, Warner G . The Patient Activation Measure: a validation study in a neurological population. Qual Life Res. 2015; 24(7):1587-96. DOI: 10.1007/s11136-014-0908-0. View

3.
Green C, Perrin N, Polen M, Leo M, Hibbard J, Tusler M . Development of the Patient Activation Measure for mental health. Adm Policy Ment Health. 2009; 37(4):327-33. PMC: 3536445. DOI: 10.1007/s10488-009-0239-6. View

4.
Zill J, Dwinger S, Kriston L, Rohenkohl A, Harter M, Dirmaier J . Psychometric evaluation of the German version of the Patient Activation Measure (PAM13). BMC Public Health. 2013; 13:1027. PMC: 4228438. DOI: 10.1186/1471-2458-13-1027. View

5.
Daud M, Ramli A, Abdul-Razak S, Isa M, Yusoff F, Baharudin N . The EMPOWER-SUSTAIN e-Health Intervention to improve patient activation and self-management behaviours among individuals with Metabolic Syndrome in primary care: study protocol for a pilot randomised controlled trial. Trials. 2020; 21(1):311. PMC: 7130454. DOI: 10.1186/s13063-020-04237-x. View